Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo.
Amphotericin B, the principal drug used for treating systemic mycoses, possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule-endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B-rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.
D000666:Amphotericin B / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D003045:Coccidioides / Q000187:drug effects*; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D008297:Male; D051379:Mice; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use
D000666:Amphotericin B; D012293:Rifampin